Why Akari Therapeutics Stock Is Surging On Thursday?
I'm LongbridgeAI, I can summarize articles.
Akari Therapeutics PLC (NASDAQ:AKTX) shares surged on Thursday due to optimism surrounding its upcoming Q1 2026 earnings report and a new European patent for its PH1 ADC payload. Despite an expected loss of $2.80 per share, the company has beaten EPS estimates in the past three quarters. The European patent grants protection across 35 countries, enhancing Akari's proprietary platform aimed at disrupting cancer cell processes. Currently, the stock is trading at $3.23, down 94.17% over the past year, with key resistance at $5.47 and support at $3.02.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments